Conformis, Inc. (CFMS)
| Market Cap | 104.85M |
| Revenue (ttm) | 71.95M |
| Net Income (ttm) | -23.10M |
| Shares Out | 71.22M |
| EPS (ttm) | -0.34 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $1.22 |
| Previous Close | $1.04 |
| Change ($) | 0.18 |
| Change (%) | 17.31% |
| Day's Open | 1.07 |
| Day's Range | 1.05 - 1.37 |
| Day's Volume | 8,175,574 |
| 52-Week Range | 0.56 - 1.37 |
Conformis (CFMS) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
BILLERICA, Mass., Dec. 31, 2020 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS), a leader in patient-specific knee and hip instrumentation and implants, announced today that Mark Augusti, C...
Cordera™ Match Hip System combines the proven Cordera™ hip stem with Conformis' state-of-the-art, personalized pre-operative plans and patient-specific instruments. Cordera™ Match Hip System c...
BILLERICA, Mass., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that Mark Augusti, President and Chief Executive Officer, and Robert Howe, Chief Financial Off...
BILLERICA, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that the Company has appointed Bart Lagae as its new VP, International Sales & Marketing.
Conformis's (CFMS) CEO Mark Augusti on Q3 2020 Results - Earnings Call Transcript
ConforMIS (CFMS) delivered earnings and revenue surprises of 25.00% and 0.13%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
BILLERICA, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today financial results for the third quarter ended September 30, 2020.
Conformis (NASDAQ: CFMS) releases its next round of earnings this Wednesday, November 04. Get the latest predictions in Benzinga's essential guide to the company's Q3 earnings report.
BILLERICA, Mass., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that Mark Augusti, President and Chief Executive Officer, and Robert Howe, Chief Financial Off...
ConforMIS (CFMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Call to be Hosted on November 4, 2020 Earnings Call to be Hosted on November 4, 2020
Cordera™ Hip System with optional patient-specific instrumentation and personalized surgical plan joins the 3D Conformis Hip System as the latest hip technology from Conformis Cordera™ Hip Sys...
BILLERICA, Mass., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Conformis, Inc. (Nasdaq: CFMS) today announced it has entered into a definitive agreement with a healthcare focused institutional investo...
BILLERICA, Mass., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) will participate in the 2020 Oppenheimer Fall Healthcare Life Sciences & MedTech Summit being held Septembe...
BILLERICA, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) will participate in the upcoming 2020 H.C. Wainwright 22nd Annual Global Investment Conference, to be held ...
BILLERICA, Mass., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that Mark Augusti, President and Chief Executive Officer, and members of the Company’s exec...
BILLERICA, Mass., Aug. 20, 2020 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that it completed the second of three milestones pursuant to the License Agreement and Devel...
BILLERICA, Mass., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that the Company has appointed Farzin Khaghani as its new VP, US Marketing.
Clinical research published online in July 2020 in The Journal of Bone and Joint Surgery Reviews found that the patients studied, who all received Conformis patient-specific iTotal PS (posteri...
ConforMIS (CFMS) delivered earnings and revenue surprises of 76.92% and 32.93%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Conformis' (CFMS) CEO Mark Augusti on Q2 2020 Results - Earnings Call Transcript
BILLERICA, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today financial results for the second quarter ended June 30, 2020.
BILLERICA, Mass., July 23, 2020 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that management will present at the Canaccord Genuity 40th Annual Growth Conference. The eve...
ConforMIS (CFMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Call to be Hosted on August 5, 2020
Conformis' (CFMS) latest iTotal Identity PS Knee System clears FDA hurdle, paving the way for providing better patient-specific pre-operative surgical plans.
iTotal® Identity PS joins iTotal® Identity CR as the latest personalized knee technology from Conformis iTotal® Identity PS joins iTotal® Identity CR as the latest personalized knee technology...
Conformis and Zimmer Biomet settled disputes related to Patient-Specific Instrument Patents for Use with Off-the-Shelf Knee, Hip, and Shoulder Implants Conformis and Zimmer Biomet settled disp...
Dr. Malte Asseln awarded annual prize by German Society for Biomedical Engineering at the VDE Association and the Klee Family Foundation for his scientific computer-and-image-based workflow to...
Conformis (CFMS) CEO Mark Augusti on Q1 2020 Results - Earnings Call Transcript
ConforMIS (CFMS) delivered earnings and revenue surprises of -55.56% and -13.04%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
ConforMIS (CFMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BILLERICA, Mass., April 20, 2020 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) today announced that on April 17, 2020 the Company entered into a $4,719,800 promissory note with East West...
Inside the top-ranked stocks that have been exhibiting rising P/E ratios.
Conformis, Inc. (CFMS) CEO Mark Augusti on Q4 2019 Results - Earnings Call Transcript
ConforMIS (CFMS) delivered earnings and revenue surprises of 20.00% and -0.09%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Rating Highlights Positive Five-Year Survivorship Following Total Knee Arthroplasty Rating Highlights Positive Five-Year Survivorship Following Total Knee Arthroplasty
Also Announces Gary Maingot as SVP, Operations; New Executive Leadership Team Members Contribute Deep Functional Expertise and Technical Knowledge; Inducement Grants Reported Also Announces Ga...
Conformis: An Update On The New Total Hip Replacement System
Conformis’ Patient-Specific Knee Implant Technology Is Complemented by New 3D-designed Hip System Launched in November 2019 Conformis’ Patient-Specific Knee Implant Technology Is Complemented ...
BILLERICA, Mass. and SAN FRANCISCO, Jan. 14, 2020 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology p...
Athenex Mixed Results, Boston Scientific Approval, And Other News: The Good, Bad, And Ugly Of Biopharma
Inside the best performing stocks of the Russell 2000 ETF.
Conformis' (CFMS) CEO Mark Augusti on Q3 2019 Results - Earnings Call Transcript
ConforMIS (CFMS) delivered earnings and revenue surprises of -18.18% and -2.77%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
ConforMIS (CFMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BILLERICA, Mass., Oct. 04, 2019 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop...
Conformis Inc. (NASDAQ: CFMS) shares shot up on Tuesday after the firm announced that it has entered into definitive agreements to sell and license to Stryker Corp.
About CFMS
Conformis, a medical technology company, develops, manufactures, and sells joint replacement implants. The company offers personalized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a personalized bicompartmental knee replacement system; and iUni, a personalized unicompartmental knee replacement product to treat the medial or lateral compartment of the knee. It also provides Conformis Hip System, a hip replacement product; and iJigs, a customized... [Read more...]
| Industry Medical Devices | IPO Date Jul 1, 2015 |
| CEO Mark A. Augusti | Employees 262 |
| Stock Exchange NASDAQ | Ticker Symbol CFMS |
Financial Performance
In 2019, Conformis's revenue was $77.43 million, a decrease of -13.77% compared to the previous year's $89.79 million. Losses were -$28.48 million, -34.33% less than in 2018.
Analyst Forecasts
According to 4 analysts, the average rating for Conformis stock is "Buy." The 12-month stock price forecast is 2.33, which is an increase of 90.98% from the latest price.